Replies to post #96870 on Biotech Values

[jbog]

Considering that Biogen just got another 13 more years tacked onto its Avonex drug, I'm sure Teva is looking at extending the patent.

[Bio_pete]

Re: Teva’s ‘low-volume’ Copaxone

I don't see how you can call it a gimmick if the new formulation succeeds in extending the patent protection. Whether or not its a medical advance is secondary however the low volume formulation showed less pain & fewer & less severe reactions.

The low volume had a greater percentage of adverse events, but these must have been minor events such as itching.

I think TEVA wins on both counts.